Chemotherapy News and Research

Latest Chemotherapy News and Research

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

29 Jul 2026

Researchers find potential pathway to improve glioblastoma treatment

New research published in Neuro-Oncology gives a glimpse at promising discoveries that could help shape the future of glioblastoma treatment and patient outcomes.

29 Jul 2026

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026

Brain cancer Achilles heel revealed in the hours after surgery

Scientists in Britain and Spain have discovered critical windows after glioblastoma surgery when the brain’s defenses falter, creating a rare chance to deliver powerful treatments exactly where needed.

29 Jul 2026

New human tissue model tracks aggressive brain tumor infiltration

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs.

28 Jul 2026

New AI tool predicts bowel cancer relapse risk from routine slides

A new artificial intelligence (AI) tool developed by La Trobe University researchers could help predict which stage-two bowel cancer patients are at risk of relapse, in an advance that could ultimately lead to thousands getting life-saving treatment earlier.

28 Jul 2026

AI reveals effective combination therapy for advanced rectal cancer

Artificial intelligence developed by researchers at UCL has revealed a promising combination of cancer treatments that could help patients with locally advanced rectal cancer live longer.

27 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Engineered probiotic bacteria boost immune attack against pancreatic cancer

Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major reason is that pancreatic tumors often create a "cold" tumor microenvironment, where the tumor prevents immune cells from mounting a strong attack.

24 Jul 2026

Two microscopic parasites cause widespread diarrheal illness across America

You've seen the alarming headlines about parasites causing "explosive diarrhea" across the U.S. Two microscopic parasites – cyclospora cayetanensis and cryptosporidium – can both cause prolonged gastrointestinal illness, including watery diarrhea, stomach cramps, and dehydration.

24 Jul 2026

Chemotherapy leaves early genomic fingerprints in childhood tumors

Nearly half of childhood tumors treated with common types of chemotherapy showed detectable DNA changes linked to treatment within 18 months, according to a new international study led by The Hospital for Sick Children (SickKids).

23 Jul 2026

New mechanism behind chemotherapy resistance in ovarian cancer discovered

Scientists at The Wistar Institute have identified a new mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal.

23 Jul 2026

UVA researchers develop a new experimental approach to target glioblastoma

University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer.

22 Jul 2026

City of Hope launches trial to map how tumors change during immunotherapy resistance

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system's ability to fight disease.

21 Jul 2026

Oral drug avatrombopag reduces chemotherapy treatment delays, trial finds

In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.

20 Jul 2026

Infectious disease expert explains who faces the highest risk from cyclosporiasis

People across the United States are taking a closer look at their lettuce and leafy greens this summer thanks to an outbreak of cyclosporiasis, a gastrointestinal illness that causes several symptoms, the most notable being severe, watery diarrhea.

19 Jul 2026

Multimodal surgery improves outcomes for rare corpus callosum glioma

Brain tumor surgeries are particularly challenging due to the difficult trade-off neurosurgeons often face—remove more tumor and risk neurological injury, or preserve function and leave more tumor behind.

17 Jul 2026

New approach enhances radiotherapy by disabling cancer's DNA repair machinery

Cancer treatments like radiation and chemotherapy work by doing one main thing: shredding the DNA of cancer cells so they can no longer multiply.

16 Jul 2026

LIG1 loss reveals new treatment strategy for aggressive breast cancer

Loss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage.

16 Jul 2026

Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.

16 Jul 2026